European Network for blood pressure research in children and adolescents (COST Action CA 19115)
High blood pressure is a clearly established modifiable risk factor for cardiovascular and renal disease. Although most of its adverse effects develop in adulthood, it has become clear that high BP is a lifelong problem that can manifest early in life. While few would dispute the importance of takin...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | Spanish |
Published: |
Elsevier
2021-06-01
|
Series: | Anales de Pediatría (English Edition) |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2341287921000272 |
id |
doaj-0f4a9ab846ba490095e23116e17729d0 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
Spanish |
format |
Article |
sources |
DOAJ |
author |
Empar Lurbe Fernando Fernandez-Aranda Elke Wühl |
spellingShingle |
Empar Lurbe Fernando Fernandez-Aranda Elke Wühl European Network for blood pressure research in children and adolescents (COST Action CA 19115) Anales de Pediatría (English Edition) Niños Adolescentes Presión arterial COST Action |
author_facet |
Empar Lurbe Fernando Fernandez-Aranda Elke Wühl |
author_sort |
Empar Lurbe |
title |
European Network for blood pressure research in children and adolescents (COST Action CA 19115) |
title_short |
European Network for blood pressure research in children and adolescents (COST Action CA 19115) |
title_full |
European Network for blood pressure research in children and adolescents (COST Action CA 19115) |
title_fullStr |
European Network for blood pressure research in children and adolescents (COST Action CA 19115) |
title_full_unstemmed |
European Network for blood pressure research in children and adolescents (COST Action CA 19115) |
title_sort |
european network for blood pressure research in children and adolescents (cost action ca 19115) |
publisher |
Elsevier |
series |
Anales de Pediatría (English Edition) |
issn |
2341-2879 |
publishDate |
2021-06-01 |
description |
High blood pressure is a clearly established modifiable risk factor for cardiovascular and renal disease. Although most of its adverse effects develop in adulthood, it has become clear that high BP is a lifelong problem that can manifest early in life. While few would dispute the importance of taking effective steps to identify and manage this condition in middle-aged and elderly individuals, relatively little attention has been paid to the problem of high BP in children and adolescents.Therefore, the development of actions focused on early childhood, childhood and adolescence and the investigation of the underlying causes of this epidemic are of utmost importance. There is a pressing need for comprehensive pan-European action to increase the knowledge on the prevention, diagnosis and treatment of high blood pressure in children and adolescents, the current scarcity of which impedes the development of consensus across different research fields and hinders efforts to introduce changes in clinical practice. There are some aspects that demand urgent action: the definition of hypertension, the prevalence of high BP in Europe, accurate measurement for early identification, the assessment of hypertension-mediated organ damage and the development and implementation of prevention strategies. In order to provide answers to all of these unanswered questions and challenges, a multidisciplinary network was established, maintained and funded by the European Cooperation in Science and Technology (COST) Association. COST is a funding organization for the creation of research networks known as COST Actions. In this case, the network will promote coordinated and collaborative activities on personalized preventive measures for children and adolescents across Europe. Resumen: La hipertensión arterial es un factor de riesgo cardiovascular y renal modificable. Aunque la mayoría de los resultados adversos ocurren en la edad adulta, la hipertensión arterial puede estar presente en etapas tempranas de la vida. Mientras pocos cuestionan la importancia de implementar medidas para identificar y manejar esta afección en personas adultas, se ha prestado relativamente poca atención al problema de la hipertensión arterial en niños y adolescentes.Conocer los orígenes de la hipertensión arterial es un tema que cada vez está más presente en los foros de debate. En este sentido, es absoluta la necesidad de una acción paneuropea con el fin de profundizar en los conocimientos sobre la prevención, el diagnóstico y el tratamiento de la hipertensión arterial en niños y adolescentes. En particular, existen algunas áreas urgentes de intervención tales como la definición de hipertensión, su prevalencia en Europa, la medición precisa para la identificación temprana de valores anormales, la evaluación del daño orgánico mediado por la hipertensión y cómo llevar a cabo estrategias de prevención. Con el fin de proporcionar respuestas a todas estas preguntas, la Comisión Europea ha aprobado y financiado una Asociación de Cooperación Europea en Ciencia y Tecnología (COST). La COST financia la creación de redes de investigación, que en nuestro caso promoverán actividades coordinadas y colaborativas sobre los problemas que presenta la hipertensión arterial en niños y adolescentes. |
topic |
Niños Adolescentes Presión arterial COST Action |
url |
http://www.sciencedirect.com/science/article/pii/S2341287921000272 |
work_keys_str_mv |
AT emparlurbe europeannetworkforbloodpressureresearchinchildrenandadolescentscostactionca19115 AT fernandofernandezaranda europeannetworkforbloodpressureresearchinchildrenandadolescentscostactionca19115 AT elkewuhl europeannetworkforbloodpressureresearchinchildrenandadolescentscostactionca19115 |
_version_ |
1721396563469664256 |
spelling |
doaj-0f4a9ab846ba490095e23116e17729d02021-06-05T06:09:24ZspaElsevierAnales de Pediatría (English Edition)2341-28792021-06-01946421.e1421.e4European Network for blood pressure research in children and adolescents (COST Action CA 19115)Empar Lurbe0Fernando Fernandez-Aranda1Elke Wühl2Hospital General, Universidad de Valencia, Valencia, Spain; CIBER Fisiopatología Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain; Corresponding author.CIBER Fisiopatología Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain; Servicio de Psiquiatría, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain; Departamento de Ciencias Clínicas, Facultad de Medicina, Universidad de Barcelona, Barcelona, SpainCentro de Pediatría y Medicina de la Adolescencia, Hospital Universitario de Heidelberg, Heidelberg, GermanyHigh blood pressure is a clearly established modifiable risk factor for cardiovascular and renal disease. Although most of its adverse effects develop in adulthood, it has become clear that high BP is a lifelong problem that can manifest early in life. While few would dispute the importance of taking effective steps to identify and manage this condition in middle-aged and elderly individuals, relatively little attention has been paid to the problem of high BP in children and adolescents.Therefore, the development of actions focused on early childhood, childhood and adolescence and the investigation of the underlying causes of this epidemic are of utmost importance. There is a pressing need for comprehensive pan-European action to increase the knowledge on the prevention, diagnosis and treatment of high blood pressure in children and adolescents, the current scarcity of which impedes the development of consensus across different research fields and hinders efforts to introduce changes in clinical practice. There are some aspects that demand urgent action: the definition of hypertension, the prevalence of high BP in Europe, accurate measurement for early identification, the assessment of hypertension-mediated organ damage and the development and implementation of prevention strategies. In order to provide answers to all of these unanswered questions and challenges, a multidisciplinary network was established, maintained and funded by the European Cooperation in Science and Technology (COST) Association. COST is a funding organization for the creation of research networks known as COST Actions. In this case, the network will promote coordinated and collaborative activities on personalized preventive measures for children and adolescents across Europe. Resumen: La hipertensión arterial es un factor de riesgo cardiovascular y renal modificable. Aunque la mayoría de los resultados adversos ocurren en la edad adulta, la hipertensión arterial puede estar presente en etapas tempranas de la vida. Mientras pocos cuestionan la importancia de implementar medidas para identificar y manejar esta afección en personas adultas, se ha prestado relativamente poca atención al problema de la hipertensión arterial en niños y adolescentes.Conocer los orígenes de la hipertensión arterial es un tema que cada vez está más presente en los foros de debate. En este sentido, es absoluta la necesidad de una acción paneuropea con el fin de profundizar en los conocimientos sobre la prevención, el diagnóstico y el tratamiento de la hipertensión arterial en niños y adolescentes. En particular, existen algunas áreas urgentes de intervención tales como la definición de hipertensión, su prevalencia en Europa, la medición precisa para la identificación temprana de valores anormales, la evaluación del daño orgánico mediado por la hipertensión y cómo llevar a cabo estrategias de prevención. Con el fin de proporcionar respuestas a todas estas preguntas, la Comisión Europea ha aprobado y financiado una Asociación de Cooperación Europea en Ciencia y Tecnología (COST). La COST financia la creación de redes de investigación, que en nuestro caso promoverán actividades coordinadas y colaborativas sobre los problemas que presenta la hipertensión arterial en niños y adolescentes.http://www.sciencedirect.com/science/article/pii/S2341287921000272NiñosAdolescentesPresión arterialCOST Action |